A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice
Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Robert L. Coleman(Texas Oncology), Jaime Anderson(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Jeffry J. Cutrera(The University of Texas MD Anderson Cancer Center), Katherine Cain(The University of Texas MD Anderson Cancer Center), Valerie F Villanueva(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Cynae Johnson(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Sara E. Sharafi(The University of Texas MD Anderson Cancer Center), Andrea S. Dickens(The University of Texas MD Anderson Cancer Center), Marlana Klinger(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k